CVI Holdings LLC Takes Position in BioLineRx Ltd. (NASDAQ:BLRX)

CVI Holdings LLC acquired a new stake in shares of BioLineRx Ltd. (NASDAQ:BLRX) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 815,683 shares of the biotechnology company’s stock, valued at approximately $462,000. CVI Holdings LLC owned approximately 1.02% of BioLineRx as of its most recent filing with the SEC.

Separately, PVG Asset Management Corp purchased a new position in BioLineRx in the 4th quarter worth $97,000. Hedge funds and other institutional investors own 1.56% of the company’s stock.

BioLineRx Price Performance

Shares of NASDAQ:BLRX opened at $0.62 on Friday. The stock has a market cap of $49.56 million, a PE ratio of -0.82 and a beta of 1.46. The company’s fifty day moving average is $0.69 and its 200 day moving average is $0.73. BioLineRx Ltd. has a 52 week low of $0.51 and a 52 week high of $2.03. The company has a quick ratio of 1.49, a current ratio of 1.61 and a debt-to-equity ratio of 1.34.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings data on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The firm had revenue of $5.39 million during the quarter, compared to analysts’ expectations of $3.93 million. Research analysts anticipate that BioLineRx Ltd. will post -0.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of BioLineRx from a “sell” rating to a “hold” rating in a research report on Monday, June 3rd.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.